1/15
04:17 pm
oncy
Oncolytics Biotech® Announces Results of Special Meeting of Shareholders [Yahoo! Finance]
Medium
Report
Oncolytics Biotech® Announces Results of Special Meeting of Shareholders [Yahoo! Finance]
1/15
04:01 pm
oncy
Oncolytics Biotech® Announces Results of Special Meeting of Shareholders
Medium
Report
Oncolytics Biotech® Announces Results of Special Meeting of Shareholders
1/14
10:39 am
oncy
The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era
Medium
Report
The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era
1/14
10:15 am
oncy
THE SOVEREIGN MANDATE: 5 Stocks Securing the 2026 Choke Points
Medium
Report
THE SOVEREIGN MANDATE: 5 Stocks Securing the 2026 Choke Points
1/14
09:00 am
oncy
Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics
Medium
Report
Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics
1/12
11:24 am
oncy
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 [Globe and Mail, The (Toronto, Canada)]
Medium
Report
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 [Globe and Mail, The (Toronto, Canada)]
1/12
10:14 am
oncy
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff
Low
Report
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff
1/12
09:00 am
oncy
Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer
Low
Report
Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer
1/12
04:40 am
oncy
Oncolytics Biotech (ONCY) Leadership Strengthens As Pelareorep Advances [Yahoo! Finance]
Low
Report
Oncolytics Biotech (ONCY) Leadership Strengthens As Pelareorep Advances [Yahoo! Finance]
1/10
09:18 am
oncy
Oncolytics outlines strategic rationale for proposal to change jurisdiction [Yahoo! Finance]
Medium
Report
Oncolytics outlines strategic rationale for proposal to change jurisdiction [Yahoo! Finance]
1/9
09:47 am
oncy
Oncolytics Biotech® Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada [Yahoo! Finance]
Medium
Report
Oncolytics Biotech® Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada [Yahoo! Finance]
1/9
09:00 am
oncy
Oncolytics Biotech® Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada
Low
Report
Oncolytics Biotech® Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada
1/8
01:28 pm
oncy
The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech [Canadian Business Journal (Canada)]
Low
Report
The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech [Canadian Business Journal (Canada)]
1/8
12:08 pm
oncy
The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech
Medium
Report
The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech
1/8
09:00 am
oncy
Oncolytics Biotech® Provides Update on Intellectual Property Strategy and Patent Filings
Medium
Report
Oncolytics Biotech® Provides Update on Intellectual Property Strategy and Patent Filings
1/7
01:28 pm
oncy
THE CHOKE POINT: 5 Assets That Control the Bottleneck [Canadian Business Journal (Canada)]
Low
Report
THE CHOKE POINT: 5 Assets That Control the Bottleneck [Canadian Business Journal (Canada)]
1/7
12:15 pm
oncy
THE CHOKE POINT: 5 Assets That Control the Bottleneck
Low
Report
THE CHOKE POINT: 5 Assets That Control the Bottleneck
1/7
10:51 am
oncy
How $594B in Precision Tech is Cracking the Metastatic Cancer Code [Globe and Mail, The (Toronto, Canada)]
Low
Report
How $594B in Precision Tech is Cracking the Metastatic Cancer Code [Globe and Mail, The (Toronto, Canada)]
1/7
10:02 am
oncy
Oncolytics Biotech® Expands Its Gastrointestinal Tumor Scientific Advisory Board with the Addition of Dr. Eileen O'Reilly, Dr. Neil Segal, and Dr. Van Morris [Yahoo! Finance]
Medium
Report
Oncolytics Biotech® Expands Its Gastrointestinal Tumor Scientific Advisory Board with the Addition of Dr. Eileen O'Reilly, Dr. Neil Segal, and Dr. Van Morris [Yahoo! Finance]
1/7
09:00 am
oncy
Oncolytics Biotech® Expands Its Gastrointestinal Tumor Scientific Advisory Board with the Addition of Dr. Eileen O’Reilly, Dr. Neil Segal, and Dr. Van Morris
Low
Report
Oncolytics Biotech® Expands Its Gastrointestinal Tumor Scientific Advisory Board with the Addition of Dr. Eileen O’Reilly, Dr. Neil Segal, and Dr. Van Morris
12/31
07:52 am
oncy
Smart Oncology: 5 Stocks Chasing the $317B Prize [Globe and Mail, The (Toronto, Canada)]
Low
Report
Smart Oncology: 5 Stocks Chasing the $317B Prize [Globe and Mail, The (Toronto, Canada)]
12/16
01:28 pm
oncy
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards [Canadian Business Journal (Canada)]
Medium
Report
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards [Canadian Business Journal (Canada)]
12/16
12:18 pm
oncy
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
Medium
Report
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
12/16
09:00 am
oncy
Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer
Medium
Report
Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer
12/15
11:28 am
oncy
THE VISIBILITY INDEX: 5 Companies Solving the Invisible Crisis [Canadian Business Journal (Canada)]
Medium
Report
THE VISIBILITY INDEX: 5 Companies Solving the Invisible Crisis [Canadian Business Journal (Canada)]